Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Sidoti & Co. Downgrades Co-Diagnostics to Neutral, Announces $5 Price Target

Sidoti & Co. analyst James Sidoti downgrades Co-Diagnostics (NASDAQ:CODX) from Buy to Neutral and announces $5 price target.
byBenzinga Newsdesk
August 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Sidoti & Co. analyst James Sidoti downgrades Co-Diagnostics (NASDAQ:CODX) from Buy to Neutral and announces $5 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Alexandria Real Estate Equities, Inc. Announces Accelerated Delivery Of Moderna’s New 462,100 RSF HQ And R&D Center, Designed To Be The Most Sustainable Laboratory Building In Cambridge, At 325 Binney Street On The One Kendall Square Mega Campus

By Benzinga Newsdesk
October 3, 8:41 AM
Alexandria earned the 2023 Visionary Award from the Cambridge Chamber of Commerce for developing325 Binney Street, which will support Moderna as it advances a pipeline of mRNA medicines thatleverage its paradigm-shifting

ARE